CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

OPTIS™ Integrated System

 

The OPTIS™ Integrated System optimises PCI1

  • This always-on, always-ready system is installed in the cath lab, eliminating setup time, and providing tableside control of OCT and FFR acquisition
  • In addition to workflow efficiencies offered by direct proximity, the on-demand availability helps enhance PCI procedures
OPTIS™ Integrated System

Want more information about OPTIS™ Imaging System?

Reach out today to Abbott.

Reach out now

The OPTIS™ Integrated System provides stunning intra-lesional detail with real-time OCT 3D visualisation, FFR combine with OCT informs PCI planning and decision making

  • Lesion location and functional significance
  • Plaque morphology characterisation2,3
  • Lesion preparation
  • Stent sizing and placement decisions4
  • Optimal approaches to bifurcation stenting4
  • Placement and apposition evaluations5
  • Post-dilatation decisions
  • Functional gain post-PCI
 

 

Abbott’s Coronary Intervention Portfolio

 

References:
1. De Bruyne, B., Pijls, N., Kalesan, B., Barbato, E., Tonino, P. A., Piroth, Z., … FAME 2 Trial Investigators. (2012). Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. New England Journal of Medicine, 367, 991-1001. 
2. Kubo, T., Imanishi, T., Takarada, S., Kuroi, A., Ueno, S., … Akasaka, T. (2007). Assessment of culprit lesion morphology in acute myocardial infarction. Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. Journal of the American College of Cardiology, 50, 933-939. 
3. Tearney, G. J., Regar, E., Akasaka, T., Adriaenssens, T., Barlis, P., Bezerra, H. G., … International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT). (2012). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. Journal of the American College of Cardiology, 59, 1058-1072. 
4. Kubo, T., Akasaka, T., Shite, J., Suzuki, T., Uemura, S., Yu, B., … Zhang, S. (2013). OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study. JACC. Cardiovascular Imaging, 6, 1095-1104. 
5. Allahwala, U., Cockburn, J., Shaw, E., Figtree, G. A., Hansen, P. S., Bhindi, R. (2015). Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular

Date of preparation: May 2021. SFM_ABO1755.

MAT-2105204 v1.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285

Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939

© 2024 Abbott. All Rights Reserved.

MAT-2105201 v6.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

 MAT-2408064 V1.0